J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock.
J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.
Quick take
Read original at Yahoo Finance Intuitive Surgical's shares fell after Johnson & Johnson received FDA authorization for its Ottava surgical robot. Analysts doubt J&J's new product will significantly impact Intuitive's market due to surgeons' established preferences and training on Intuitive's da Vinci system.
Summarised by netranta from Yahoo Finance. Open the original for the full story.
Observations (0)
Log in to add an observation.
No observations yet — add the first.